Chemoprevention of Gastric Carcinogenesis

Research Group(s)

  • Gastrointestinal and Other Cancers

Sponsor

Vanderbilt-Ingram Cancer Center

Status

Active, not recruiting

ClinicalTrials.gov ID

For more information, see ClinicalTrials.gov NCT02794428

A clinical study of the efficacy of oral alpha-difluoromethylornithine (eflornithine or DFMO)
in male and female subjects ages 30-60 with gastric premalignant lesions in two high risk
regions of Latin America.

Intervention

Eflornithine, Eflornithine placebo

Condition

Gastric Cancer, Gastric Intestinal Metaplasia

Investigators

Doug Morgan, MD, Keith Wilson, MD

See list of participating sites